Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
The Endocrine Society's 2023 obesity pharmacotherapy guideline states: "When a patient does not achieve adequate weight loss on a maximally tolerated dose of a GLP-1 receptor agonist, switching to an agent with a broader receptor profile is a reasonable escalation strategy, provided the patient is counseled on the investigational status of newer agents" [5]
Both agents have demonstrated generally favourable safety profiles in clinical trials, though Retatrutides long-term safety data is still being collected through ongoing clinical trials
Weight Loss Medication
However, it should be noted as mentioned previously, in conditions where it does not increase glucose oxidation, carnitine supplementation worsens both injury and recovery of contractile function after transient ischemia in the perfused rat heart [122]
US$ 21.03
US$ 21.23
US$ 21.91
US$ 25.51
US$ 23.19
